Based on the hypothesis that the expression of MET and VEGF are mechanisms of acquired resistance to EGFR TKIs in NSCLC tumors [2, 9, 11, 20], the phase Ib/II study reported here tested whether cabozantinib, alone or in combination with continued EGFR inhibition, was tolerable and active in patients with advanced NSCLC who had progressed after benefiting from erlotinib therapy. This evidence concerns the gene MET and non-small cell lung carcinoma.